Gemcitabine (Standard)

Gemcitabine (Standard) is the analytical standard of Gemcitabine. This product is intended for research and analytical applications. Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].

Product Specifications

CAS Number

[95058-81-4]

Product Name Alternative

LY 188011 (Standard)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog; Reference Standards

Type

Reference Standards

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gemcitabine-standard.html

Purity

99.99

Smiles

NC(C=CN1[C@H]2C(F)(F)[C@H](O)[C@@H](CO)O2)=NC1=O

Molecular Formula

C9H11F2N3O4

Molecular Weight

263.20

Precautions

H302, H315, H319, H335

References & Citations

[1]Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31 (10) :3171-80.|[2]Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194.|[3]Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18 (2) :198-206|[4]Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30 (7) :574-589.